Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

2.1 Osimertinib (Tagrisso, AstraZeneca) is indicated for 'adjuvant treatment after complete tumour resection in adult patients with stage 1b to 3a non‑small‑cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price for thirty 80 mg tablets is £5,770 (BNF online, accessed July 2021).

2.4 The company has a commercial arrangement. This makes osimertinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.